Search

Your search keyword '"Cervantes F."' showing total 45 results
Start Over Author "Cervantes F." Publication Type Electronic Resources
45 results on '"Cervantes F."'

1. Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Author

Hochhaus, A, Gambacorti Passerini, C, Abboud, C, Gjertsen, B, Brummendorf, T, Smith, B, Ernst, T, Giraldo-Castellano, P, Olsson-Stromberg, U, Saussele, S, Bardy-Bouxin, N, Viqueira, A, Leip, E, Russell-Smith, T, Leone, J, Rosti, G, Watts, J, Giles, F, Abruzzese, E, Akard, L, Bosi, A, Cervantes, F, Charbonnier, A, Di Raimondo, F, Etienne, G, Garcia Gutierrez, V, Guerci-Bresler, A, Hjorth-Hansen, H, Karsenti, J, Kelly, K, Le Coutre, P, Martinez Chamorro, C, Oehler, V, Orti Pascual, G, Petzer, A, Pungolino, E, Rege-Cambrin, G, Rigal-Huguet, F, Roboz, G, Rousselot, P, Sanchez-Guijo, F, Sanz Santillana, G, Schafhausen, P, Scheid, C, Schmidt, S, Specchia, G, Steegmann, J, Stenke, L, Hochhaus A., Gambacorti Passerini C., Abboud C., Gjertsen B. T., Brummendorf T. H., Smith B. D., Ernst T., Giraldo-Castellano P., Olsson-Stromberg U., Saussele S., Bardy-Bouxin N., Viqueira A., Leip E., Russell-Smith T. A., Leone J., Rosti G., Watts J., Giles F. J., Abruzzese E., Akard L. P., Bosi A., Cervantes F., Charbonnier A., Di Raimondo F., Etienne G., Garcia Gutierrez V., Guerci-Bresler A. P., Hjorth-Hansen H., Karsenti J. M., Kelly K. R., Le Coutre P., Martinez Chamorro C., Oehler V. G., Orti Pascual G., Petzer A., Pungolino E., Rege-Cambrin G., Rigal-Huguet F., Roboz G. J., Rousselot P., Sanchez-Guijo F. M., Sanz Santillana G., Schafhausen P., Scheid C., Schmidt S., Specchia G., Steegmann J. L., Stenke L., Hochhaus, A, Gambacorti Passerini, C, Abboud, C, Gjertsen, B, Brummendorf, T, Smith, B, Ernst, T, Giraldo-Castellano, P, Olsson-Stromberg, U, Saussele, S, Bardy-Bouxin, N, Viqueira, A, Leip, E, Russell-Smith, T, Leone, J, Rosti, G, Watts, J, Giles, F, Abruzzese, E, Akard, L, Bosi, A, Cervantes, F, Charbonnier, A, Di Raimondo, F, Etienne, G, Garcia Gutierrez, V, Guerci-Bresler, A, Hjorth-Hansen, H, Karsenti, J, Kelly, K, Le Coutre, P, Martinez Chamorro, C, Oehler, V, Orti Pascual, G, Petzer, A, Pungolino, E, Rege-Cambrin, G, Rigal-Huguet, F, Roboz, G, Rousselot, P, Sanchez-Guijo, F, Sanz Santillana, G, Schafhausen, P, Scheid, C, Schmidt, S, Specchia, G, Steegmann, J, Stenke, L, Hochhaus A., Gambacorti Passerini C., Abboud C., Gjertsen B. T., Brummendorf T. H., Smith B. D., Ernst T., Giraldo-Castellano P., Olsson-Stromberg U., Saussele S., Bardy-Bouxin N., Viqueira A., Leip E., Russell-Smith T. A., Leone J., Rosti G., Watts J., Giles F. J., Abruzzese E., Akard L. P., Bosi A., Cervantes F., Charbonnier A., Di Raimondo F., Etienne G., Garcia Gutierrez V., Guerci-Bresler A. P., Hjorth-Hansen H., Karsenti J. M., Kelly K. R., Le Coutre P., Martinez Chamorro C., Oehler V. G., Orti Pascual G., Petzer A., Pungolino E., Rege-Cambrin G., Rigal-Huguet F., Roboz G. J., Rousselot P., Sanchez-Guijo F. M., Sanz Santillana G., Schafhausen P., Scheid C., Schmidt S., Specchia G., Steegmann J. L., and Stenke L.

Abstract

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-negative/BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%, respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs.

Published
2020

2. Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases

Author

Sant'Antonio, E., Guglielmelli, P., Pieri, L., Primignani, M., Randi, M. L., Santarossa, C., Rumi, E., Cervantes, F., Delaini, F., Carobbio, A., Betti, S., Rossi, Elena, Lavi, N., Harrison, C. N., Curto-Garcia, N., Gisslinger, H., Gisslinger, B., Specchia, G., Ricco, A., Vianelli, N., Polverelli, N., Koren-Michowitz, M., Ruggeri, M., Girodon, F., Ellis, M., Iurlo, A., Mannelli, F., Mannelli, L., Sordi, B., Loscocco, G. G., Cazzola, M., De Stefano, Valerio, Barbui, T., Tefferi, A., Vannucchi, A. M., Rossi E. (ORCID:0000-0002-7572-9379), De Stefano V. (ORCID:0000-0002-5178-5827), Sant'Antonio, E., Guglielmelli, P., Pieri, L., Primignani, M., Randi, M. L., Santarossa, C., Rumi, E., Cervantes, F., Delaini, F., Carobbio, A., Betti, S., Rossi, Elena, Lavi, N., Harrison, C. N., Curto-Garcia, N., Gisslinger, H., Gisslinger, B., Specchia, G., Ricco, A., Vianelli, N., Polverelli, N., Koren-Michowitz, M., Ruggeri, M., Girodon, F., Ellis, M., Iurlo, A., Mannelli, F., Mannelli, L., Sordi, B., Loscocco, G. G., Cazzola, M., De Stefano, Valerio, Barbui, T., Tefferi, A., Vannucchi, A. M., Rossi E. (ORCID:0000-0002-7572-9379), and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Myeloproliferative Neoplasms (MPN) course can be complicated by thrombosis involving unusual sites as the splanchnic veins (SVT). Their management is challenging, given their composite vascular risk. We performed a retrospective, cohort study in the framework of the International Working Group for MPN Research and Treatment (IWG-MRT), and AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM). A total of 518 MPN-SVT cases were collected and compared with 1628 unselected, control MPN population, matched for disease subtype. Those with MPN-SVT were younger (median 44 years) and enriched in females compared to controls; PV (37.1%) and ET (34.4%) were the most frequent diagnoses. JAK2V617F mutation was highly prevalent (90.2%), and 38.6% of cases had an additional hypercoagulable disorder. SVT recurrence rate was 1.6 per 100 patient-years. Vitamin K-antagonists (VKA) halved the incidence of recurrence (OR 0.48), unlike cytoreduction (OR 0.96), and were not associated with overall or gastrointestinal bleeding in multivariable analysis. Esophageal varices were the only independent predictor for major bleeding (OR 17.4). Among MPN-SVT, risk of subsequent vascular events was skewed towards venous thromboses compared to controls. However, MPN-SVT clinical course was overall benign: SVT were enriched in PMF with lower IPSS, resulting in significantly longer survival than controls; survival was not affected in PV and slightly reduced in ET. MPN-U with SVT (n = 55) showed a particularly indolent phenotype, with no signs of disease evolution. In the to-date largest, contemporary cohort of MPN-SVT, VKA were confirmed effective in preventing recurrence, unlike cytoreduction, and safe; the major risk factor for bleeding was esophageal varices that therefore represent a major therapeutic target.

Published
2020

3. Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group

Author

Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J. -J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Albano, F., Benevolo, G., Cavalloni, C., Uccella, S., Accetta, R., Siracusa, C., Agnoli, S., Merli, M., Barbui, T., Bertu, L., Cazzola, M., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Barraco, D., Rambaldi, A., Caramella, M., Komrokji, R. S., Kiladjian, J. -J., Gotlib, J., Iurlo, A., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Albano, F., Benevolo, G., Cavalloni, C., Uccella, S., Accetta, R., Siracusa, C., Agnoli, S., Merli, M., Barbui, T., Bertu, L., Cazzola, M., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2020

4. Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients

Author

Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Giorgino, T., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Rumi, E., Guglielmelli, P., Barraco, D., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Giorgino, T., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient-years. When including non-melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patientyears. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.

Published
2019

5. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project

Author

Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Merli, M., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Giorgino, T., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Barraco, D., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Merli, M., Pietra, D., Barbui, T., Rotunno, G., Cazzola, M., Giorgino, T., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

6. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC project

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Merli, M., Pietra, D., Casalone, R., Barbui, T., Rotunno, G., Cazzola, M., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

7. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia

Author

Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Pietra, D., Barbui, T., Rotunno, G., Vannucchi, A. M., Passamonti, F., De Stefano V. (ORCID:0000-0002-5178-5827), Mora, B., Giorgino, T., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Cavalloni, C., Barraco, D., Pietra, D., Barbui, T., Rotunno, G., Vannucchi, A. M., Passamonti, F., and De Stefano V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2018

8. Which patients with myelofibrosis should receive ruxolitinib therapy? : ELN-SIE evidence-based recommendations

Author

Marchetti, M., Barosi, G., Cervantes, F., Birgegård, Gunnar, Griesshammer, M., Harrison, C., Hehlmann, R., Kiladjian, J-J, Kroeger, N., McMullin, M. F., Passamonti, F., Vannucchi, A., Barbui, T., Marchetti, M., Barosi, G., Cervantes, F., Birgegård, Gunnar, Griesshammer, M., Harrison, C., Hehlmann, R., Kiladjian, J-J, Kroeger, N., McMullin, M. F., Passamonti, F., Vannucchi, A., and Barbui, T.

Abstract

Ruxolitinib is an oral Janus-activated kinase 1 (JAK1)/JAK2 inhibitor approved for the treatment of patients with myelofibrosis based on the results of two randomized clinical trials. However, discordant indications were provided by regulatory agencies and scientific societies for selecting the most appropriate candidates to this drug. The European LeukemiaNet and the Italian Society of Hematology shared the aim of building evidence-based recommendations for the use of ruxolitinib according to the GRADE methodology. Eighteen patient-intervention-comparator-outcome profiles were listed, each of them comparing ruxolitinib to other therapies with the aim of improving one of the three clinical outcomes: (a) splenomegaly, (b) disease-related symptoms, and (c) survival. Ruxolitinib was strongly recommended for improving symptomatic or severe (415 cm below the costal margin) splenomegaly in patients with an International Prognostic Scoring System (IPSS)/dynamic IPSS risk intermediate 2 or high. Ruxolitinib was also strongly recommended for improving systemic symptoms in patients with an MPN10 score 444, refractory severe itching, unintended weight loss not attributable to other causes or unexplained fever. Because of weak evidence, the panel does not recommend ruxolitinib therapy for improving survival. Also, the recommendations given above do not necessarily apply to patients who are candidates for allogeneic stem cell transplant.

Published
2017
Full Text
View/download PDF

9. Driver mutations' effect in secondary myelofibrosis: An international multicenter study based on 781 patients

Author

Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R., Benevolo, G., Albano, F., Caramazza, D., Rumi, E., Merli, M., Pietra, D., Casalone, R., Barbui, T., Pieri, L., Vannucchi, A. M., De Stefano, V. (ORCID:0000-0002-5178-5827), Passamonti, F., Mora, B., Giorgino, T., Guglielmelli, P., Cazzola, M., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, V., Ruggeri, M., Silver, R., Benevolo, G., Albano, F., Caramazza, D., Rumi, E., Merli, M., Pietra, D., Casalone, R., Barbui, T., Pieri, L., Vannucchi, A. M., and De Stefano, V. (ORCID:0000-0002-5178-5827)

Abstract

N/A

Published
2017

10. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

Author

Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., Vannucchi, A. M., De Stefano, V. (ORCID:0000-0002-5178-5827), Passamonti, F., Giorgino, T., Mora, B., Guglielmelli, P., Rumi, E., Maffioli, M., Rambaldi, A., Caramella, M., Komrokji, R., Gotlib, J., Kiladjian, J. J., Cervantes, F., Devos, T., Palandri, F., De Stefano, Valerio, Ruggeri, M., Silver, R. T., Benevolo, G., Albano, F., Caramazza, D., Merli, M., Pietra, D., Casalone, R., Rotunno, G., Barbui, T., Cazzola, M., Vannucchi, A. M., and De Stefano, V. (ORCID:0000-0002-5178-5827)

Abstract

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms with variable risk of evolution into post-PV and post-ET myelofibrosis, from now on referred to as secondary myelofibrosis (SMF). No specific tools have been defined for risk stratification in SMF. To develop a prognostic model for predicting survival, we studied 685 JAK2, CALR, and MPL annotated patients with SMF. Median survival of the whole cohort was 9.3 years (95% CI: 8-not reached-NR-). Through penalized Cox regressions we identified negative predictors of survival and according to beta risk coefficients we assigned 2 points to hemoglobin level o 11 g/dl, to circulating blasts 3%, and to CALR-unmutated genotype, 1 point to platelet count o 150 × 109/l and to constitutional symptoms, and 0.15 points to any year of age. Myelofibrosis Secondary to PV and ET-Prognostic Model (MYSEC-PM) allocated SMF patients into four risk categories with different survival (P o 0.0001): low (median survival NR; 133 patients), intermediate-1 (9.3 years, 95% CI: 8.1-NR; 245 patients), intermediate-2 (4.4 years, 95% CI: 3.2–7.9; 126 patients), and high risk (2 years, 95% CI: 1.7–3.9; 75 patients). Finally, we found that the MYSEC-PM represents the most appropriate tool for SMF decision-making to be used in clinical and trial settings.

Published
2017

11. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia

Author

Pfirrmann, M., Baccarani, M., Saussele, S., Guilhot, J., Cervantes, F., Ossenkoppele, G., Hoffmann, V. S., Castagnetti, F., Hasford, J., Hehlmann, R., Simonsson, Bengt, Pfirrmann, M., Baccarani, M., Saussele, S., Guilhot, J., Cervantes, F., Ossenkoppele, G., Hoffmann, V. S., Castagnetti, F., Hasford, J., Hehlmann, R., and Simonsson, Bengt

Abstract

In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%. Many patients die of reasons unrelated to CML. This work tackled the reassessment of prognosis under particular consideration of the probabilities of dying of CML. Analyses were based on 2290 patients with chronic phase CML treated with imatinib in six clinical trials. 'Death due to CML' was defined by death after disease progression. At 8 years, OS was 89%. Of 208 deceased patients, 44% died of CML. Higher age, more peripheral blasts, bigger spleen and low platelet counts were significantly associated with increased probabilities of dying of CML and determined a new long-term survival score with three prognostic groups. Compared with the low-risk group, the patients of the intermediate-and the high-risk group had significantly higher probabilities of dying of CML. The score was successfully validated in an independent sample of 1120 patients. In both samples, the new score differentiated probabilities of dying of CML better than the Sokal, Euro and the European Treatment and Outcome Study (EUTOS) score. The new score identified 61% low-risk patients with excellent long-term outcome and 12% high-risk patients. The new score supports the prospective assessment of long-term antileukemic efficacy and risk-adapted treatment.

Published
2016
Full Text
View/download PDF

12. SYMPTOMS, RISK CLASSIFICATION, AND SPLEEN SIZE IN JAK2 INHIBITOR-NAIVE MYELOFIBROSIS : IMPLICATIONS FOR JAK2 INHIBITOR TREATMENT

Author

Scherber, R., Dueck, A., Geyer, H., Kosiorek, H., Kiladjian, J. J., Slot, S., Zweegman, S., Boekhorst, P., Schouten, H., Sackmann, F., Fuentes, A., Hernandez-Maraver, D., Pahl, H., Stegelmann, F., Doehner, K., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Harrison, C., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P., Barosi, G., Vannucchi, A., Passamonti, F., Andreasson, B., Samuelsson, J., Birgegård, Gunnar, Sun, X., Xu, J., Zhang, P., Xu, Z., Barbui, T., Senyak, Z., Grieshammer, M., Rambaldi, A., Ferrari, M., Lehmann, T., Mesa, R., Scherber, R., Dueck, A., Geyer, H., Kosiorek, H., Kiladjian, J. J., Slot, S., Zweegman, S., Boekhorst, P., Schouten, H., Sackmann, F., Fuentes, A., Hernandez-Maraver, D., Pahl, H., Stegelmann, F., Doehner, K., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Harrison, C., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P., Barosi, G., Vannucchi, A., Passamonti, F., Andreasson, B., Samuelsson, J., Birgegård, Gunnar, Sun, X., Xu, J., Zhang, P., Xu, Z., Barbui, T., Senyak, Z., Grieshammer, M., Rambaldi, A., Ferrari, M., Lehmann, T., and Mesa, R.

Published
2016

13. Development Of An Mf Patient Reported Outcome (Pro) Tool For Fda Qualification : Comprehensive Literature Search And Physician Cognitive Debriefing Results

Author

Geyer, H., Kosiorek, H., Dueck, A., Slot, S., Zweegman, S., Kiladjian, J. J., Boekhorst, P., Schouten, H., Sackmann, F., Fuentes, A., Hernandez-Maraver, D., Pahl, H., Stegelmann, F., Doehner, K., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Harrison, C., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P., Barosi, G., Passamonti, F., Andreasson, B., Samuelsson, J., Birgegård, Gunnar, Sun, X., Xu, J., Zhang, P., Xu, Z., Barbui, T., Senyak, Z., Grieshammer, M., Rambaldi, A., Ferrari, M., Lehmann, T., Scherber, R., Mesa, R., Geyer, H., Kosiorek, H., Dueck, A., Slot, S., Zweegman, S., Kiladjian, J. J., Boekhorst, P., Schouten, H., Sackmann, F., Fuentes, A., Hernandez-Maraver, D., Pahl, H., Stegelmann, F., Doehner, K., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Harrison, C., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P., Barosi, G., Passamonti, F., Andreasson, B., Samuelsson, J., Birgegård, Gunnar, Sun, X., Xu, J., Zhang, P., Xu, Z., Barbui, T., Senyak, Z., Grieshammer, M., Rambaldi, A., Ferrari, M., Lehmann, T., Scherber, R., and Mesa, R.

Published
2016

14. Impact Of Splenomegaly On Mpn Symptoms And Association With Clinical Features : An Analysis By The Mpn Quality Of Life International Study Group

Author

Geyer, H., Scherber, R., Kosiorek, H., Dueck, A., Kiladjian, J. J., Slot, S., Zweegman, S., Boekhorst, P., Schouten, H., Sackmann, F., Fuentes, A., Hernandez-Maraver, D., Pahl, H., Stegelmann, F., Doehner, K., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Harrison, C., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P., Barosi, G., Vannucchi, A., Passamonti, F., Andreasson, B., Samuelsson, J., Birgegård, Gunnar, Sun, X., Xu, J., Zhang, P., Xu, Z., Barbui, T., Senyak, Z., Grieshammer, M., Rambaldi, A., Ferrari, M., Lehmann, T., Mesa, R., Geyer, H., Scherber, R., Kosiorek, H., Dueck, A., Kiladjian, J. J., Slot, S., Zweegman, S., Boekhorst, P., Schouten, H., Sackmann, F., Fuentes, A., Hernandez-Maraver, D., Pahl, H., Stegelmann, F., Doehner, K., Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Harrison, C., Radia, D., Muxi, P., Maldonado, N., Besses, C., Cervantes, F., Johansson, P., Barosi, G., Vannucchi, A., Passamonti, F., Andreasson, B., Samuelsson, J., Birgegård, Gunnar, Sun, X., Xu, J., Zhang, P., Xu, Z., Barbui, T., Senyak, Z., Grieshammer, M., Rambaldi, A., Ferrari, M., Lehmann, T., and Mesa, R.

Published
2016

15. The European Hematology Association Roadmap for European Hematology Research: a consensus document.

Author

EHA Roadmap for European Hematology, Research, Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Döhner, H., de Wit TD., Eichinger, S., Fibbe, W., Green, T., de Haas, F., Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, JJ., André, M., Andre-Schmutz, I., Bacigalupo, A., Bochud, PY., Boer, Md., Bonini, C., Camaschella, C., Cant, A., Cappellini, MD., Cazzola, M., Celso, CL., Dimopoulos, M., Douay, L., Dzierzak, E., Einsele, H., Ferreri, A., De Franceschi, L., Gaulard, P., Gottgens, B., Greinacher, A., Gresele, P., Gribben, J., de Haan, G., Hansen, JB., Hochhaus, A., Kadir, R., Kaveri, S., Kouskoff, V., Kühne, T., Kyrle, P., Ljungman, P., Maschmeyer, G., Méndez-Ferrer£££Simón£££ S., Milsom, M., Mummery, C., Ossenkoppele, G., Pecci, A., Peyvandi, F., Philipsen, S., Reitsma, P., Ribera, JM., Risitano, A., Rivella, S., Ruf, W., Schroeder, T., Scully, M., Socie, G., Staal, F., Stanworth, S., Stauder, R., Stilgenbauer, S., Tamary, H., Theilgaard-Mönch, K., Thein, SL., Tilly, H., Trneny, M., Vainchenker, W., Vannucchi, AM., Viscoli, C., Vrielink, H., Zaaijer, H., Zanella, A., Zolla, L., Zwaginga, JJ., Martinez, PA., van den Akker, E., Allard, S., Anagnou, N., Andolfo, I., Andrau, JC., Angelucci, E., Anstee, D., Aurer, I., Avet-Loiseau, H., Aydinok, Y., Bakchoul, T., Balduini, A., Barcellini, W., Baruch, D., Baruchel, A., Bayry, J., Bento, C., van den Berg, A., Bernardi, R., Bianchi, P., Bigas, A., Biondi, A., Bohonek, M., Bonnet, D., Borchmann, P., Borregaard, N., Brækkan, S., van den Brink, M., Brodin, E., Bullinger, L., Buske, C., Butzeck, B., Cammenga, J., Campo, E., Carbone, A., Cervantes, F., Cesaro, S., Charbord, P., Claas, F., Cohen, H., Conard, J., Coppo, P., Corrons, JL., Costa, Ld., Davi, F., Delwel, R., Dianzani, I., Domanović, D., Donnelly, P., Drnov?ek£££Tadeja Dovč£££ TD., Dreyling, M., Du, MQ., Dufour, C., Durand, C., Efremov, D., Eleftheriou, A., Elion, J., Emonts, M., Engelhardt, M., Ezine, S., Falkenburg, F., Favier, R., Federico, M., Fenaux, P., Fitzgibbon, J., Flygare, J., Foà, R., Forrester, L., Galacteros, F., Garagiola, I., Gardiner, C., Garraud, O., van Geet, C., Geiger, H., Geissler, J., Germing, U., Ghevaert, C., Girelli, D., Godeau, B., Gökbuget, N., Goldschmidt, H., Goodeve, A., Graf, T., Graziadei, G., Griesshammer, M., Gruel, Y., Guilhot, F., von Gunten, S., Gyssens, I., Halter, J., Harrison, C., Harteveld, C., Hellström-Lindberg, E., Hermine, O., Higgs, D., Hillmen, P., Hirsch, H., Hoskin, P., Huls, G., Inati, A., Johnson, P., Kattamis, A., Kiefel, V., Kleanthous, M., Klump, H., Krause, D., Hovinga, JK., Lacaud, G., Lacroix-Desmazes, S., Landman-Parker, J., LeGouill, S., Lenz, G., von Lilienfeld-Toal, M., von Lindern, M., Lopez-Guillermo, A., Lopriore, E., Lozano, M., MacIntyre, E., Makris, M., Mannhalter, C., Martens, J., Mathas, S., Matzdorff, A., Medvinsky, A., Menendez, P., Migliaccio, AR., Miharada, K., Mikulska, M., Minard, V., Montalbán, C., de Montalembert, M., Montserrat, E., Morange, PE., Mountford, J., Muckenthaler, M., Müller-Tidow, C., Mumford, A., Nadel, B., Navarro, JT., Nemer, We., Noizat-Pirenne, F., O'Mahony, B., Oldenburg, J., Olsson, M., Oostendorp, R., Palumbo, A., Passamonti, F., Patient, R., Peffault, R., Pflumio, F., Pierelli, L., Piga, A., Pollard, D., Raaijmakers, M., Radford, J., Rambach, R., Rao, AK., Raslova, H., Rebulla, P., Rees, D., Ribrag, V., Rijneveld, A., Rinalducci, S., Robak, T., Roberts, I., Rodrigues, C., Rosendaal, F., Rosenwald, A., Rule, S., Russo, R., Saglio, G., Sanchez, M., Scharf, RE., Schlenke, P., Semple, J., Sierra, J., So-Osman, C., Soria, JM., Stamatopoulos, K., Stegmayr, B., Stunnenberg, H., Swinkels, D., Barata£££João Pedro Taborda£££ JP., Taghon, T., Taher, A., Terpos, E., Thachil, J., Tissot, JD., Touw, I., Toye, A., Trappe, R., Traverse-Glehen, A., Unal, S., Vaulont, S., Viprakasit, V., Vitolo, U., van Wijk, R., Wójtowicz, A., Zeerleder, S., Zieger, B., de Wit, T.D., Schuringa, J.J., EHA Roadmap for European Hematology, Research, Engert, A., Balduini, C., Brand, A., Coiffier, B., Cordonnier, C., Döhner, H., de Wit TD., Eichinger, S., Fibbe, W., Green, T., de Haas, F., Iolascon, A., Jaffredo, T., Rodeghiero, F., Salles, G., Schuringa, JJ., André, M., Andre-Schmutz, I., Bacigalupo, A., Bochud, PY., Boer, Md., Bonini, C., Camaschella, C., Cant, A., Cappellini, MD., Cazzola, M., Celso, CL., Dimopoulos, M., Douay, L., Dzierzak, E., Einsele, H., Ferreri, A., De Franceschi, L., Gaulard, P., Gottgens, B., Greinacher, A., Gresele, P., Gribben, J., de Haan, G., Hansen, JB., Hochhaus, A., Kadir, R., Kaveri, S., Kouskoff, V., Kühne, T., Kyrle, P., Ljungman, P., Maschmeyer, G., Méndez-Ferrer£££Simón£££ S., Milsom, M., Mummery, C., Ossenkoppele, G., Pecci, A., Peyvandi, F., Philipsen, S., Reitsma, P., Ribera, JM., Risitano, A., Rivella, S., Ruf, W., Schroeder, T., Scully, M., Socie, G., Staal, F., Stanworth, S., Stauder, R., Stilgenbauer, S., Tamary, H., Theilgaard-Mönch, K., Thein, SL., Tilly, H., Trneny, M., Vainchenker, W., Vannucchi, AM., Viscoli, C., Vrielink, H., Zaaijer, H., Zanella, A., Zolla, L., Zwaginga, JJ., Martinez, PA., van den Akker, E., Allard, S., Anagnou, N., Andolfo, I., Andrau, JC., Angelucci, E., Anstee, D., Aurer, I., Avet-Loiseau, H., Aydinok, Y., Bakchoul, T., Balduini, A., Barcellini, W., Baruch, D., Baruchel, A., Bayry, J., Bento, C., van den Berg, A., Bernardi, R., Bianchi, P., Bigas, A., Biondi, A., Bohonek, M., Bonnet, D., Borchmann, P., Borregaard, N., Brækkan, S., van den Brink, M., Brodin, E., Bullinger, L., Buske, C., Butzeck, B., Cammenga, J., Campo, E., Carbone, A., Cervantes, F., Cesaro, S., Charbord, P., Claas, F., Cohen, H., Conard, J., Coppo, P., Corrons, JL., Costa, Ld., Davi, F., Delwel, R., Dianzani, I., Domanović, D., Donnelly, P., Drnov?ek£££Tadeja Dovč£££ TD., Dreyling, M., Du, MQ., Dufour, C., Durand, C., Efremov, D., Eleftheriou, A., Elion, J., Emonts, M., Engelhardt, M., Ezine, S., Falkenburg, F., Favier, R., Federico, M., Fenaux, P., Fitzgibbon, J., Flygare, J., Foà, R., Forrester, L., Galacteros, F., Garagiola, I., Gardiner, C., Garraud, O., van Geet, C., Geiger, H., Geissler, J., Germing, U., Ghevaert, C., Girelli, D., Godeau, B., Gökbuget, N., Goldschmidt, H., Goodeve, A., Graf, T., Graziadei, G., Griesshammer, M., Gruel, Y., Guilhot, F., von Gunten, S., Gyssens, I., Halter, J., Harrison, C., Harteveld, C., Hellström-Lindberg, E., Hermine, O., Higgs, D., Hillmen, P., Hirsch, H., Hoskin, P., Huls, G., Inati, A., Johnson, P., Kattamis, A., Kiefel, V., Kleanthous, M., Klump, H., Krause, D., Hovinga, JK., Lacaud, G., Lacroix-Desmazes, S., Landman-Parker, J., LeGouill, S., Lenz, G., von Lilienfeld-Toal, M., von Lindern, M., Lopez-Guillermo, A., Lopriore, E., Lozano, M., MacIntyre, E., Makris, M., Mannhalter, C., Martens, J., Mathas, S., Matzdorff, A., Medvinsky, A., Menendez, P., Migliaccio, AR., Miharada, K., Mikulska, M., Minard, V., Montalbán, C., de Montalembert, M., Montserrat, E., Morange, PE., Mountford, J., Muckenthaler, M., Müller-Tidow, C., Mumford, A., Nadel, B., Navarro, JT., Nemer, We., Noizat-Pirenne, F., O'Mahony, B., Oldenburg, J., Olsson, M., Oostendorp, R., Palumbo, A., Passamonti, F., Patient, R., Peffault, R., Pflumio, F., Pierelli, L., Piga, A., Pollard, D., Raaijmakers, M., Radford, J., Rambach, R., Rao, AK., Raslova, H., Rebulla, P., Rees, D., Ribrag, V., Rijneveld, A., Rinalducci, S., Robak, T., Roberts, I., Rodrigues, C., Rosendaal, F., Rosenwald, A., Rule, S., Russo, R., Saglio, G., Sanchez, M., Scharf, RE., Schlenke, P., Semple, J., Sierra, J., So-Osman, C., Soria, JM., Stamatopoulos, K., Stegmayr, B., Stunnenberg, H., Swinkels, D., Barata£££João Pedro Taborda£££ JP., Taghon, T., Taher, A., Terpos, E., Thachil, J., Tissot, JD., Touw, I., Toye, A., Trappe, R., Traverse-Glehen, A., Unal, S., Vaulont, S., Viprakasit, V., Vitolo, U., van Wijk, R., Wójtowicz, A., Zeerleder, S., Zieger, B., de Wit, T.D., and Schuringa, J.J.

Abstract

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at euro23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap.The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders.The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

Published
2016

16. The european hematology association roadmap for european hematology research: A consensus document

Author

Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, BIONDI, ANDREA, Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, and BIONDI, ANDREA

Abstract

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

Published
2016

17. The european hematology association roadmap for european hematology research: A consensus document

Author

Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, BIONDI, ANDREA, Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Döhner, H, De Wit, T, Eichinger, S, Fibbe, W, Green, T, De Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Sall Es, G, Schuringa, J, André, M, Andre Schmutz, I, Bacigalupo, A, Bochud, P, Den Boer, M, Bonini, C, Camaschella, C, Cant, A, Cappellini, M, Cazzola, M, Celso, C, Dimopoulos, M, Douay, L, Dzierzak, E, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, De Haan, G, Hansen, J, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kühne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Méndez Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, S, Reitsma, P, Ribera, J, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard Mönch, K, Thein, S, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, A, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, J, Martinez, P, Van Den Akker, E, Allard, S, Anagnou, N, Andolfo, I, Andrau, J, Angelucci, E, Anstee, D, Aurer, I, Avet Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, Van Den Berg, A, Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Brækkan, S, Van Den Brink, M, Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Vives Corron, J, Da Costa, L, Davi, F, Delwel, R, Dianzani, I, Domanović, D, Donnelly, P, Drnovšek, T, Dreyling, M, Du, M, Dufour, C, Durand, C, Efremov, D, Eleftheriou, A, Elion, J, Emonts, M, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foà, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, Van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gökbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, Von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellström Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, J, Lacaud, G, Lacroix Desmazes, S, Landman Parker, J, Legouill, S, Lenz, G, Von Lilienfeld Toal, M, Von Lindern, M, Lopez Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Mannhalter, C, Martens, J, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, A, Miharada, K, Mikulska, M, Minard, V, Montalbán, C, De Montalembert, M, Montserrat, E, Morange, P, Mountford, J, Muckenthaler, M, Müller Tidow, C, Mumford, A, Nadel, B, Navarro, J, El Nemer, W, Noizat Pirenne, F, O’Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, De Latour, R, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Koneti Rao, A, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, A, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, R, Schlenke, P, Semple, J, Sierra, J, So Osman, C, Soria, J, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, J, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, J, Touw, I, Toye, A, Trappe, R, Traverse Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, Van Wijk, R, Wójtowicz, A, Zeerleder, S, Zieger, B, Zieger, B., ZANELLA, ALBERTO, and BIONDI, ANDREA

Abstract

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at ∈ European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better fu treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine ‘sections’ in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

Published
2016

18. The European Hematology Association Roadmap for European Hematology Research: a consensus document

Author

Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Dohner, H, de Wit, TD, Eichinger, S, Fibbe, W, Green, T, de Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Salles, G, Schuringa, JJ, Andre, M, Andre-Schmutz, I, Bacigalupo, A, Bochud, PY, den Boer, Monique, Bonini, C, Camaschella, C, Cant, A, Cappellini, MD, Cazzola, M, Lo Celso, C, Dimopoulos, M, Douay, L, Dzierzak, Elaine, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, de Haan, G, Hansen, JB, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kuhne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Mendez-Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, Sjaak, Reitsma, P, Ribera, JM, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard-Monch, K, Thein, SL, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, AM, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, JJ, Martinez, PA, van den Akker, E, Allard, S, Anagnou, N, Andrau, JC, Angelucci, E, Anstee, D, Aurer, I, Avet-Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, van den Berg, A (Andrea), Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Braekkan, S, ten Brink, M (Mirian), Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Corrons, JLV, da Costa, L, Davi, F, Delwel, Ruud, Dianzani, I, Domanovic, D, Donnelly, P, Drnovsek, TD, Dreyling, M, Du, MQ, Durand, CML (Charles), Efremov, D, Eleftheriou, A, Elion, J, Emonts, Marieke, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foa, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gokbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellstrom-Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, JK, Lacaud, G, Lacroix-Desmazes, S, Landman-Parker, J, LeGouill, S, Lenz, G, von Lilienfeld-Toal, M, Lindern, Marieke, Lopez-Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Martens, John, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, AR, Miharada, K, Mikulska, M, Minard, V, Montalban, C, de Montalembert, M, Montserrat, E, Morange, PE, Mountford, J, Muckenthaler, M, Muller-Tidow, C, Mumford, A, Nadel, B, Navarro, JT, el Nemer, W, Noizat-Pirenne, F, O'Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, de Latour, RP, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Rao, AK, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, Anita, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, RE, Schlenke, P, Semple, J, Sierra, J, So-Osman, C, Soria, JM, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, JPT, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, JD, Touw, Ivo, Toye, A, Trappe, R, Traverse-Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, van Wijk, R, Wojtowicz, A, Zeerleder, S, Zieger, B, Engert, A, Balduini, C, Brand, A, Coiffier, B, Cordonnier, C, Dohner, H, de Wit, TD, Eichinger, S, Fibbe, W, Green, T, de Haas, F, Iolascon, A, Jaffredo, T, Rodeghiero, F, Salles, G, Schuringa, JJ, Andre, M, Andre-Schmutz, I, Bacigalupo, A, Bochud, PY, den Boer, Monique, Bonini, C, Camaschella, C, Cant, A, Cappellini, MD, Cazzola, M, Lo Celso, C, Dimopoulos, M, Douay, L, Dzierzak, Elaine, Einsele, H, Ferreri, A, De Franceschi, L, Gaulard, P, Gottgens, B, Greinacher, A, Gresele, P, Gribben, J, de Haan, G, Hansen, JB, Hochhaus, A, Kadir, R, Kaveri, S, Kouskoff, V, Kuhne, T, Kyrle, P, Ljungman, P, Maschmeyer, G, Mendez-Ferrer, S, Milsom, M, Mummery, C, Ossenkoppele, G, Pecci, A, Peyvandi, F, Philipsen, Sjaak, Reitsma, P, Ribera, JM, Risitano, A, Rivella, S, Ruf, W, Schroeder, T, Scully, M, Socie, G, Staal, F, Stanworth, S, Stauder, R, Stilgenbauer, S, Tamary, H, Theilgaard-Monch, K, Thein, SL, Tilly, H, Trneny, M, Vainchenker, W, Vannucchi, AM, Viscoli, C, Vrielink, H, Zaaijer, H, Zanella, A, Zolla, L, Zwaginga, JJ, Martinez, PA, van den Akker, E, Allard, S, Anagnou, N, Andrau, JC, Angelucci, E, Anstee, D, Aurer, I, Avet-Loiseau, H, Aydinok, Y, Bakchoul, T, Balduini, A, Barcellini, W, Baruch, D, Baruchel, A, Bayry, J, Bento, C, van den Berg, A (Andrea), Bernardi, R, Bianchi, P, Bigas, A, Biondi, A, Bohonek, M, Bonnet, D, Borchmann, P, Borregaard, N, Braekkan, S, ten Brink, M (Mirian), Brodin, E, Bullinger, L, Buske, C, Butzeck, B, Cammenga, J, Campo, E, Carbone, A, Cervantes, F, Cesaro, S, Charbord, P, Claas, F, Cohen, H, Conard, J, Coppo, P, Corrons, JLV, da Costa, L, Davi, F, Delwel, Ruud, Dianzani, I, Domanovic, D, Donnelly, P, Drnovsek, TD, Dreyling, M, Du, MQ, Durand, CML (Charles), Efremov, D, Eleftheriou, A, Elion, J, Emonts, Marieke, Engelhardt, M, Ezine, S, Falkenburg, F, Favier, R, Federico, M, Fenaux, P, Fitzgibbon, J, Flygare, J, Foa, R, Forrester, L, Galacteros, F, Garagiola, I, Gardiner, C, Garraud, O, van Geet, C, Geiger, H, Geissler, J, Germing, U, Ghevaert, C, Girelli, D, Godeau, B, Gokbuget, N, Goldschmidt, H, Goodeve, A, Graf, T, Graziadei, G, Griesshammer, M, Gruel, Y, Guilhot, F, von Gunten, S, Gyssens, I, Halter, J, Harrison, C, Harteveld, C, Hellstrom-Lindberg, E, Hermine, O, Higgs, D, Hillmen, P, Hirsch, H, Hoskin, P, Huls, G, Inati, A, Johnson, P, Kattamis, A, Kiefel, V, Kleanthous, M, Klump, H, Krause, D, Hovinga, JK, Lacaud, G, Lacroix-Desmazes, S, Landman-Parker, J, LeGouill, S, Lenz, G, von Lilienfeld-Toal, M, Lindern, Marieke, Lopez-Guillermo, A, Lopriore, E, Lozano, M, Macintyre, E, Makris, M, Martens, John, Mathas, S, Matzdorff, A, Medvinsky, A, Menendez, P, Migliaccio, AR, Miharada, K, Mikulska, M, Minard, V, Montalban, C, de Montalembert, M, Montserrat, E, Morange, PE, Mountford, J, Muckenthaler, M, Muller-Tidow, C, Mumford, A, Nadel, B, Navarro, JT, el Nemer, W, Noizat-Pirenne, F, O'Mahony, B, Oldenburg, J, Olsson, M, Oostendorp, R, Palumbo, A, Passamonti, F, Patient, R, de Latour, RP, Pflumio, F, Pierelli, L, Piga, A, Pollard, D, Raaijmakers, M, Radford, J, Rambach, R, Rao, AK, Raslova, H, Rebulla, P, Rees, D, Ribrag, V, Rijneveld, Anita, Rinalducci, S, Robak, T, Roberts, I, Rodrigues, C, Rosendaal, F, Rosenwald, A, Rule, S, Russo, R, Saglio, G, Sanchez, M, Scharf, RE, Schlenke, P, Semple, J, Sierra, J, So-Osman, C, Soria, JM, Stamatopoulos, K, Stegmayr, B, Stunnenberg, H, Swinkels, D, Barata, JPT, Taghon, T, Taher, A, Terpos, E, Thachil, J, Tissot, JD, Touw, Ivo, Toye, A, Trappe, R, Traverse-Glehen, A, Unal, S, Vaulont, S, Viprakasit, V, Vitolo, U, van Wijk, R, Wojtowicz, A, Zeerleder, S, and Zieger, B

Abstract

The European Hematology Association (EHA) Roadmap for European Hematology Research highlights major achievements in diagnosis and treatment of blood disorders and identifies the greatest unmet clinical and scientific needs in those areas to enable better funded, more focused European hematology research. Initiated by the EHA, around 300 experts contributed to the consensus document, which will help European policy makers, research funders, research organizations, researchers, and patient groups make better informed decisions on hematology research. It also aims to raise public awareness of the burden of blood disorders on European society, which purely in economic terms is estimated at (sic)23 billion per year, a level of cost that is not matched in current European hematology research funding. In recent decades, hematology research has improved our fundamental understanding of the biology of blood disorders, and has improved diagnostics and treatments, sometimes in revolutionary ways. This progress highlights the potential of focused basic research programs such as this EHA Roadmap. The EHA Roadmap identifies nine 'sections' in hematology: normal hematopoiesis, malignant lymphoid and myeloid diseases, anemias and related diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine, infections in hematology, and hematopoietic stem cell transplantation. These sections span 60 smaller groups of diseases or disorders. The EHA Roadmap identifies priorities and needs across the field of hematology, including those to develop targeted therapies based on genomic profiling and chemical biology, to eradicate minimal residual malignant disease, and to develop cellular immunotherapies, combination treatments, gene therapies, hematopoietic stem cell treatments, and treatments that are better tolerated by elderly patients.

Published
2016

19. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with Vitamin K antagonists

Author

De Stefano, Valerio, Ruggeri, M., Cervantes, F., Alvarez Larrán, A., Iurlo, A., Randi, M. L., Elli, E., Finazzi, M. C., Finazzi, G., Zetterberg, E., Vianelli, N., Gaidano, G., Rossi, Elena, Betti, Silvia, Nichele, I., Cattaneo, D., Palova, M., Ellis, M. H., Cacciola, R., Tieghi, A., Hernandez Boluda, J. C., Pungolino, E., Specchia, G., Rapezzi, D., Forcina, A., Musolino, C., Carobbio, A., Griesshammer, M., Sant'Antonio, E., Vannucchi, A. M., Barbui, T., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Rossi, Elena (ORCID:0000-0002-7572-9379), De Stefano, Valerio, Ruggeri, M., Cervantes, F., Alvarez Larrán, A., Iurlo, A., Randi, M. L., Elli, E., Finazzi, M. C., Finazzi, G., Zetterberg, E., Vianelli, N., Gaidano, G., Rossi, Elena, Betti, Silvia, Nichele, I., Cattaneo, D., Palova, M., Ellis, M. H., Cacciola, R., Tieghi, A., Hernandez Boluda, J. C., Pungolino, E., Specchia, G., Rapezzi, D., Forcina, A., Musolino, C., Carobbio, A., Griesshammer, M., Sant'Antonio, E., Vannucchi, A. M., Barbui, T., De Stefano, Valerio (ORCID:0000-0002-5178-5827), and Rossi, Elena (ORCID:0000-0002-7572-9379)

Abstract

The optimal duration of treatment with vitamin K antagonists (VKA) after venous thromboembolism (VTE) in patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) is uncertain. To tackle this issue, we retrospectively studied 206 patients with MPN-related VTE (deep venous thrombosis of the legs and/or pulmonary embolism). After this index event, we recorded over 695 pt-years 45 recurrences, venous in 36 cases, with an incidence rate (IR) of 6.5 per 100 pt-years (95% confidence interval (CI): 4.9-8.6). One hundred fifty-five patients received VKA; the IR of recurrent thrombosis per 100 pt-years was 4.7 (95% CI: 2.8-7.3) on VKA and 8.9 (95% CI: 5.7-13.2) off VKA (P=0.03). In patients receiving VKA, the IR of recurrent thrombosis per 100 pt-years was 5.3 (95% CI: 3.2-8.4) among 108 patients on long-term VKA and 12.8 (95% CI: 7.3-20.7) after discontinuation among the 47 who ceased treatment (P=0.008), with a doubled risk of recurrence after stopping VKA (hazard ratio: 2.21, 95% CI: 1.19-5.30). The IR of major bleeding per 100 pt-years was 2.4 (95%: CI: 1.1-4.5) on VKA and 0.7 (95% CI: 0.08-2.5) off VKA (P=0.08). In conclusion, in MPN patients with VTE recurrent thrombosis is significantly reduced by VKA and caution should be adopted in discontinuation; however, the incidence of recurrence on treatment remains high, calling for clinical trials aimed to improve prophylaxis in this setting.

Published
2016

20. Splanchnic vein thrombosis in myeloproliferative neoplasms: Risk factors for recurrences in a cohort of 181 patients

Author

De Stefano, Valerio, Vannucchi, A. M., Ruggeri, M., Cervantes, F., Alvarez Larrán, A., Iurlo, A., Randi, M. L., Pieri, L., Rossi, Elena, Guglielmelli, P., Betti, Silvia, Elli, E., Finazzi, M. C., Finazzi, G., Zetterberg, E., Vianelli, N., Gaidano, G., Nichele, I., Cattaneo, D., Palova, M., Ellis, M. H., Cacciola, E., Tieghi, A., Hernandez Boluda, J. C., Pungolino, E., Specchia, G., Rapezzi, D., Forcina, A., Musolino, C., Carobbio, A., Griesshammer, M., Barbui, T., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Rossi, Elena (ORCID:0000-0002-7572-9379), De Stefano, Valerio, Vannucchi, A. M., Ruggeri, M., Cervantes, F., Alvarez Larrán, A., Iurlo, A., Randi, M. L., Pieri, L., Rossi, Elena, Guglielmelli, P., Betti, Silvia, Elli, E., Finazzi, M. C., Finazzi, G., Zetterberg, E., Vianelli, N., Gaidano, G., Nichele, I., Cattaneo, D., Palova, M., Ellis, M. H., Cacciola, E., Tieghi, A., Hernandez Boluda, J. C., Pungolino, E., Specchia, G., Rapezzi, D., Forcina, A., Musolino, C., Carobbio, A., Griesshammer, M., Barbui, T., De Stefano, Valerio (ORCID:0000-0002-5178-5827), and Rossi, Elena (ORCID:0000-0002-7572-9379)

Abstract

We retrospectively studied 181 patients with polycythaemia vera (n=67), essential thrombocythaemia (n=67) or primary myelofibrosis (n=47), who presented a first episode of splanchnic vein thrombosis (SVT). Budd-Chiari syndrome (BCS) and portal vein thrombosis were diagnosed in 31 (17.1%) and 109 (60.3%) patients, respectively; isolated thrombosis of the mesenteric or splenic veins was detected in 18 and 23 cases, respectively. After this index event, the patients were followed for 735 patient years (pt-years) and experienced 31 recurrences corresponding to an incidence rate of 4.2 per 100 pt-years. Factors associated with a significantly higher risk of recurrence were BCS (hazard ratio (HR): 3.03), history of previous thrombosis (HR: 3.62), splenomegaly (HR: 2.66) and leukocytosis (HR: 2.8). Vitamin K-antagonists (VKA) were prescribed in 85% of patients and the recurrence rate was 3.9 per 100 pt-years, whereas in the small fraction (15%) not receiving VKA more recurrences (7.2 per 100 pt-years) were reported. Intracranial and extracranial major bleeding was recorded mainly in patients on VKA and the corresponding rate was 2.0 per 100 pt-years. In conclusion, despite anticoagulation treatment, the recurrence rate after SVT in myeloproliferative neoplasms is high and suggests the exploration of new avenues of secondary prophylaxis with new antithrombotic drugs and JAK-2 inhibitors.

Published
2016

21. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms : consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)

Author

Barosi, G, Tefferi, A, Besses, C, Birgegård, Gunnar, Cervantes, F, Finazzi, G, Gisslinger, H, Griesshammer, M, Harrison, C, Hehlmann, R, Hermouet, S, Kiladjian, J-J, Kröger, N, Mesa, R, Mc Mullin, M F, Pardanani, A, Passamonti, F, Samuelsson, J, Vannucchi, A M, Reiter, A, Silver, R T, Verstovsek, S, Tognoni, G, Barbui, T, Barosi, G, Tefferi, A, Besses, C, Birgegård, Gunnar, Cervantes, F, Finazzi, G, Gisslinger, H, Griesshammer, M, Harrison, C, Hehlmann, R, Hermouet, S, Kiladjian, J-J, Kröger, N, Mesa, R, Mc Mullin, M F, Pardanani, A, Passamonti, F, Samuelsson, J, Vannucchi, A M, Reiter, A, Silver, R T, Verstovsek, S, Tognoni, G, and Barbui, T

Abstract

The discovery of somatic mutations, primarily JAK2V617F and CALR, in classic BCR-ABL1-negative myeloproliferative neoplasms (MPNs) has generated interest in the development of molecularly targeted therapies, whose accurate assessment requires a standardized framework. A working group, comprised of members from European LeukemiaNet (ELN) and International Working Group for MPN Research and Treatment (IWG-MRT), prepared consensus-based recommendations regarding trial design, patient selection and definition of relevant end points. Accordingly, a response able to capture the long-term effect of the drug should be selected as the end point of phase II trials aimed at developing new drugs for MPNs. A time-to-event, such as overall survival, or progression-free survival or both, as co-primary end points, should measure efficacy in phase III studies. New drugs should be tested for preventing disease progression in myelofibrosis patients with early disease in randomized studies, and a time to event, such as progression-free or event-free survival should be the primary end point. Phase III trials aimed at preventing vascular events in polycythemia vera and essential thrombocythemia should be based on a selection of the target population based on new prognostic factors, including JAK2 mutation. In conclusion, we recommended a format for clinical trials in MPNs that facilitates communication between academic investigators, regulatory agencies and drug companies.

Published
2015
Full Text
View/download PDF

22. PRIMARY MYELOFIBROSIS, POST-ET AND POST-PV MYELOFIBROSIS HAVE DISTINCT CLINICAL PROFILES AND SYMPTOMATIC BURDENS : AN ANALYSIS BY THE MPN QUALITY OF LIFE INTERNATIONAL STUDY GROUP (MPN-QOL ISG)

Author

Geyer, H., Kosiorek, H., Scherber, R., Dueck, A., Jean-Jacques, K., Xiao, Z., Zweegman, S., Sackman, F., Hernandez-Maraver, D., Dohner, K., Harrison, C., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P., Andreasson, B., Rambaldi, A., Barbui, T., Vannucchi, A., Passamonti, F., Samuelsson, J., Birgegård, Gunnar, Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. -C, Ranta, D., Roy, L., Cahn, J. -Y, Maldonado, N., Barosi, G., Ferrari, M., Cannon, K., te Boekhorst, P. A. W., Klauke, K., Schouten, H., Pahl, H., Griesshammer, M., Stegelmann, F., Lehmann, T., Xu, Z., Zhang, Y., Sun, X., Xu, J., Zhang, P., Mesa, R., Geyer, H., Kosiorek, H., Scherber, R., Dueck, A., Jean-Jacques, K., Xiao, Z., Zweegman, S., Sackman, F., Hernandez-Maraver, D., Dohner, K., Harrison, C., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P., Andreasson, B., Rambaldi, A., Barbui, T., Vannucchi, A., Passamonti, F., Samuelsson, J., Birgegård, Gunnar, Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. -C, Ranta, D., Roy, L., Cahn, J. -Y, Maldonado, N., Barosi, G., Ferrari, M., Cannon, K., te Boekhorst, P. A. W., Klauke, K., Schouten, H., Pahl, H., Griesshammer, M., Stegelmann, F., Lehmann, T., Xu, Z., Zhang, Y., Sun, X., Xu, J., Zhang, P., and Mesa, R.

Published
2015

25. Order-Fractal transition in abstract paintings

Author

De la Calleja, E. M., Cervantes, F., De la Calleja, J., De la Calleja, E. M., Cervantes, F., and De la Calleja, J.

Abstract

We report the degree of order of twenty-two Jackson Pollock's paintings using \emph{Hausdorff-Besicovitch fractal dimension}. Through the maximum value of each multi-fractal spectrum, the artworks are classify by the year in which they were painted. It has been reported that Pollock's paintings are fractal and it increased on his latest works. However our results show that fractal dimension of the paintings are on a range of fractal dimension with values close to two. We identify this behavior as a fractal-order transition. Based on the study of disorder-order transition in physical systems, we interpreted the fractal-order transition through its dark paint strokes in Pollocks' paintings, as structured lines following a power law measured by fractal dimension. We obtain self-similarity in some specific Pollock's paintings, that reveal an important dependence on the scale of observation. We also characterize by its fractal spectrum, the called \emph{Teri's Find}. We obtained similar spectrums between \emph{Teri's Find} and \emph{Number 5} from Pollock, suggesting that fractal dimension cannot be completely rejected as a quantitative parameter to authenticate this kind of artworks.

Published
2015
Full Text
View/download PDF

26. Overall Survival and Prognosis in 2190 Patients with First-Line Imatinib Treatment Considering Death Due to Chronic Myeloid Leukaemia as the Only Event

Author

Pfirrmann, M., Saussele, S., Baccarani, M., Guilhot, J., Cervantes, F., Ossenkoppele, G., Lindoerfer, D., Hoffmann, Vs, Castagnetti, F., Hehlmann, R., Simonsson, Bengt, Pfirrmann, M., Saussele, S., Baccarani, M., Guilhot, J., Cervantes, F., Ossenkoppele, G., Lindoerfer, D., Hoffmann, Vs, Castagnetti, F., Hehlmann, R., and Simonsson, Bengt

Published
2014

27. Gender Differences and MPN Symptom Burden : An Analysis by the MPN Quality of Life International Study Group (MPN-QOL ISG)

Author

Geyer, H., Emanuel, R., Dueck, A., Kiladjian, J. J., Xiao, Z., Slot, S., Zweegman, S., Sackman, F., Kerguelen Fuentes, A., Hernandez-Maraver, D., Dohner, K., Harrison, C., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P., Andreasson, B., Rambaldi, A., Barbui, T., Vannucchi, A., Passamonti, F., Samuelsson, J., Birgegård, Gunnar, Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Maldonado, N., Barosi, G., Ferrari, M., Cannon, K., te Boekhorst, P. A., Klauke, K., Schouten, H., Pahl, H., Griesshammer, M., Stegelmann, F., Lehmann, T., Xu, Z., Zhang, Y., Sun, X., Xu, J., Zhang, P., Mesa, R., Geyer, H., Emanuel, R., Dueck, A., Kiladjian, J. J., Xiao, Z., Slot, S., Zweegman, S., Sackman, F., Kerguelen Fuentes, A., Hernandez-Maraver, D., Dohner, K., Harrison, C., Radia, D., Muxi, P., Besses, C., Cervantes, F., Johansson, P., Andreasson, B., Rambaldi, A., Barbui, T., Vannucchi, A., Passamonti, F., Samuelsson, J., Birgegård, Gunnar, Bonatz, K., Reiter, A., Boyer, F., Etienne, G., Ianotto, J. C., Ranta, D., Roy, L., Cahn, J. Y., Maldonado, N., Barosi, G., Ferrari, M., Cannon, K., te Boekhorst, P. A., Klauke, K., Schouten, H., Pahl, H., Griesshammer, M., Stegelmann, F., Lehmann, T., Xu, Z., Zhang, Y., Sun, X., Xu, J., Zhang, P., and Mesa, R.

Published
2014

28. Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up

Author

GAMBACORTI PASSERINI, C, Brümmendorf, T, Kim, D, Turkina, A, Masszi, T, Assouline, S, Durrant, S, Kantarjian, H, Khoury, H, Zaritskey, A, Shen, Z, Jin, J, Vellenga, E, Pasquini, R, Mathews, V, Cervantes, F, Besson, N, Turnbull, K, Leip, E, Kelly, V, Cortes, J, GAMBACORTI PASSERINI, CARLO, Cortes, J., GAMBACORTI PASSERINI, C, Brümmendorf, T, Kim, D, Turkina, A, Masszi, T, Assouline, S, Durrant, S, Kantarjian, H, Khoury, H, Zaritskey, A, Shen, Z, Jin, J, Vellenga, E, Pasquini, R, Mathews, V, Cervantes, F, Besson, N, Turnbull, K, Leip, E, Kelly, V, Cortes, J, GAMBACORTI PASSERINI, CARLO, and Cortes, J.

Abstract

Bosutinib is an orally active, dual Src/Abl tyrosine kinase inhibitor for treatment of chronic myeloid leukemia (CML) following resistance/intolerance to prior therapy. Here, we report the data from the 2-year follow-up of a phase 1/2 open-label study evaluating the efficacy and safety of bosutinib as second-line therapy in 288 patients with chronic phase CML resistant (n = 200) or intolerant (n = 88) to imatinib. The cumulative response rates to bosutinib were as follows: 85% achieved/maintained complete hematologic response, 59% achieved/maintained major cytogenetic response (including 48% with complete cytogenetic response), and 35% achieved major molecular response. Responses were durable, with 2-year estimates of retaining response >70%. Two-year probabilities of progression-free survival and overall survival were 81% and 91%, respectively. The most common toxicities were primarily gastrointestinal adverse events (diarrhea [84%], nausea [45%], vomiting [37%]), which were primarily mild to moderate, typically transient, and first occurred early during treatment. Thrombocytopenia was the most common grade 3/4 hematologic laboratory abnormality (24%). Outcomes were generally similar among imatinib-resistant and imatinib-intolerant patients and did not differ with age. The longer-term results of the present analysis confirm that bosutinib is an effective and tolerable second-line therapy for patients with imatinib-resistant or imatinib-intolerant chronic phase CML. ClinicalTrials.gov Identifier: NCT00261846. Am. J. Hematol. 89:732-742, 2014. © 2014 The Authors American Journal of Hematology Published by Wiley Periodicals, Inc

Published
2014

29. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study

Author

Martinelli, I, De Stefano, Valerio, Carobbio, A, Randi, Ml, Santarossa, C, Rambaldi, A, Finazzi, Mc, Cervantes, F, Arellano Rodrigo, E, Rupoli, S, Canafoglia, L, Tieghi, A, Facchini, L, Betti, Silvia, Vannucchi, Am, Pieri, L, Cacciola, R, Cacciola, E, Cortelezzi, A, Iurlo, A, Pogliani, Em, Elli, Em, Spadea, A, Barbui, T., De Stefano, Valerio (ORCID:0000-0002-5178-5827), Martinelli, I, De Stefano, Valerio, Carobbio, A, Randi, Ml, Santarossa, C, Rambaldi, A, Finazzi, Mc, Cervantes, F, Arellano Rodrigo, E, Rupoli, S, Canafoglia, L, Tieghi, A, Facchini, L, Betti, Silvia, Vannucchi, Am, Pieri, L, Cacciola, R, Cacciola, E, Cortelezzi, A, Iurlo, A, Pogliani, Em, Elli, Em, Spadea, A, Barbui, T., and De Stefano, Valerio (ORCID:0000-0002-5178-5827)

Abstract

To investigate the characteristics and clinical course of cerebral vein thrombosis (CVT) in patients with myeloproliferative neoplasms (MPN) we compared 48 patients with MPN and CVT (group MPN-CVT) to 87 with MPN and other venous thrombosis (group MPN-VT) and 178 with MPN and no thrombosis (group MPN-NoT) matched by sex, age at diagnosis of MPN (±5 years) and type of MPN. The study population was identified among 5,500 patients with MPN, from January 1982 to June 2013. Thrombophilia abnormalities were significantly more prevalent in the MPN-CVT and MPN-VT than in MPN-NoT group (P = 0.015), as well as the JAK2 V617F mutation in patients with essential thrombocythemia (P = 0.059). Compared to MPN-VT, MPN-CVT patients had a higher rate of recurrent thrombosis (42% vs. 25%, P = 0.049) despite a shorter median follow-up period (6.1 vs. 10.3 years, P = 0.019), a higher long-term antithrombotic (94% vs. 84%, P = 0.099) and a similar cytoreductive treatment (79% vs. 70%, P = 0.311). The incidence of recurrent thrombosis was double in MPN-CVT than in MPN-VT group (8.8% and 4.2% patient-years, P = 0.022), and CVT and unprovoked event were the only predictive variables in a multivariate model including also sex, blood count, thrombophilia, cytoreductive, and antithrombotic treatment (HR 1.97, 95%CI 1.05-3.72 and 2.09, 1.09-4.00, respectively).

Published
2014

30. Overall survival and prognosis in patients with chronic myeloid leukaemia allocated to first-line imatinib treatment - new results from the EUTOS 'In-Study' registry

Author

Pfirrmann, M., Saussele, S., Baccarani, M., Guilhot, J., Cervantes, F., Ossenkoppele, G., Lindoerfer, D., Hoffmann, V. S., Castagnetti, F., Hehlmann, R., Simonsson, Bengt, Pfirrmann, M., Saussele, S., Baccarani, M., Guilhot, J., Cervantes, F., Ossenkoppele, G., Lindoerfer, D., Hoffmann, V. S., Castagnetti, F., Hehlmann, R., and Simonsson, Bengt

Published
2013

31. The Gravitational Universe

Author

Consortium, The eLISA, Seoane, P. Amaro, Aoudia, S., Audley, H., Auger, G., Babak, S., Baker, J., Barausse, E., Barke, S., Bassan, M., Beckmann, V., Benacquista, M., Bender, P. L., Berti, E., Binétruy, P., Bogenstahl, J., Bonvin, C., Bortoluzzi, D., Brause, N. C., Brossard, J., Buchman, S., Bykov, I., Camp, J., Caprini, C., Cavalleri, A., Cerdonio, M., Ciani, G., Colpi, M., Congedo, G., Conklin, J., Cornish, N., Danzmann, K., de Vine, G., DeBra, D., Freitag, M. Dewi, Di Fiore, L., Aguilo, M. Diaz, Diepholz, I., Dolesi, R., Dotti, M., Barranco, G. Fernández, Ferraioli, L., Ferroni, V., Finetti, N., Fitzsimons, E., Gair, J., Galeazzi, F., Garcia, A., Gerberding, O., Gesa, L., Giardini, D., Gibert, F., Grimani, C., Groot, P., Cervantes, F. Guzman, Haiman, Z., Halloin, H., Heinzel, G., Hewitson, M., Hogan, C., Holz, D., Hornstrup, A., Hoyland, D., Hoyle, C. D., Hueller, M., Hughes, S., Jetzer, P., Kalogera, V., Karnesis, N., Kilic, M., Killow, C., Klipstein, W., Kochkina, E., Korsakova, N., Krolak, A., Larson, S., Lieser, M., Littenberg, T., Livas, J., Lloro, I., Mance, D., Madau, P., Maghami, P., Mahrdt, C., Marsh, T., Mateos, I., Mayer, L., McClelland, D., McKenzie, K., McWilliams, S., Merkowitz, S., Miller, C., Mitryk, S., Moerschell, J., Mohanty, S., Monsky, A., Mueller, G., Müller, V., Nelemans, G., Nicolodi, D., Nissanke, S., Nofrarias, M., Numata, K., Ohme, F., Otto, M., Perreur-Lloyd, M., Petiteau, A., Phinney, E. S., Plagnol, E., Pollack, S., Porter, E., Prat, P., Preston, A., Prince, T., Reiche, J., Richstone, D., Robertson, D., Rossi, E. M., Rosswog, S., Rubbo, L., Ruiter, A., Sanjuan, J., Sathyaprakash, B. S., Schlamminger, S., Schutz, B., Schütze, D., Sesana, A., Shaddock, D., Shah, S., Sheard, B., Sopuerta, C. F., Spector, A., Spero, R., Stanga, R., Stebbins, R., Stede, G., Steier, F., Sumner, T., Sun, K. -X., Sutton, A., Tanaka, T., Tanner, D., Thorpe, I., Tröbs, M., Tinto, M., Tu, H. -B., Vallisneri, M., Vetrugno, D., Vitale, S., Volonteri, M., Wand, V., Wang, Y., Wanner, G., Ward, H., Ware, B., Wass, P., Weber, W. J., Yu, Y., Yunes, N., Zweifel, P., Consortium, The eLISA, Seoane, P. Amaro, Aoudia, S., Audley, H., Auger, G., Babak, S., Baker, J., Barausse, E., Barke, S., Bassan, M., Beckmann, V., Benacquista, M., Bender, P. L., Berti, E., Binétruy, P., Bogenstahl, J., Bonvin, C., Bortoluzzi, D., Brause, N. C., Brossard, J., Buchman, S., Bykov, I., Camp, J., Caprini, C., Cavalleri, A., Cerdonio, M., Ciani, G., Colpi, M., Congedo, G., Conklin, J., Cornish, N., Danzmann, K., de Vine, G., DeBra, D., Freitag, M. Dewi, Di Fiore, L., Aguilo, M. Diaz, Diepholz, I., Dolesi, R., Dotti, M., Barranco, G. Fernández, Ferraioli, L., Ferroni, V., Finetti, N., Fitzsimons, E., Gair, J., Galeazzi, F., Garcia, A., Gerberding, O., Gesa, L., Giardini, D., Gibert, F., Grimani, C., Groot, P., Cervantes, F. Guzman, Haiman, Z., Halloin, H., Heinzel, G., Hewitson, M., Hogan, C., Holz, D., Hornstrup, A., Hoyland, D., Hoyle, C. D., Hueller, M., Hughes, S., Jetzer, P., Kalogera, V., Karnesis, N., Kilic, M., Killow, C., Klipstein, W., Kochkina, E., Korsakova, N., Krolak, A., Larson, S., Lieser, M., Littenberg, T., Livas, J., Lloro, I., Mance, D., Madau, P., Maghami, P., Mahrdt, C., Marsh, T., Mateos, I., Mayer, L., McClelland, D., McKenzie, K., McWilliams, S., Merkowitz, S., Miller, C., Mitryk, S., Moerschell, J., Mohanty, S., Monsky, A., Mueller, G., Müller, V., Nelemans, G., Nicolodi, D., Nissanke, S., Nofrarias, M., Numata, K., Ohme, F., Otto, M., Perreur-Lloyd, M., Petiteau, A., Phinney, E. S., Plagnol, E., Pollack, S., Porter, E., Prat, P., Preston, A., Prince, T., Reiche, J., Richstone, D., Robertson, D., Rossi, E. M., Rosswog, S., Rubbo, L., Ruiter, A., Sanjuan, J., Sathyaprakash, B. S., Schlamminger, S., Schutz, B., Schütze, D., Sesana, A., Shaddock, D., Shah, S., Sheard, B., Sopuerta, C. F., Spector, A., Spero, R., Stanga, R., Stebbins, R., Stede, G., Steier, F., Sumner, T., Sun, K. -X., Sutton, A., Tanaka, T., Tanner, D., Thorpe, I., Tröbs, M., Tinto, M., Tu, H. -B., Vallisneri, M., Vetrugno, D., Vitale, S., Volonteri, M., Wand, V., Wang, Y., Wanner, G., Ward, H., Ware, B., Wass, P., Weber, W. J., Yu, Y., Yunes, N., and Zweifel, P.

Abstract

The last century has seen enormous progress in our understanding of the Universe. We know the life cycles of stars, the structure of galaxies, the remnants of the big bang, and have a general understanding of how the Universe evolved. We have come remarkably far using electromagnetic radiation as our tool for observing the Universe. However, gravity is the engine behind many of the processes in the Universe, and much of its action is dark. Opening a gravitational window on the Universe will let us go further than any alternative. Gravity has its own messenger: Gravitational waves, ripples in the fabric of spacetime. They travel essentially undisturbed and let us peer deep into the formation of the first seed black holes, exploring redshifts as large as z ~ 20, prior to the epoch of cosmic re-ionisation. Exquisite and unprecedented measurements of black hole masses and spins will make it possible to trace the history of black holes across all stages of galaxy evolution, and at the same time constrain any deviation from the Kerr metric of General Relativity. eLISA will be the first ever mission to study the entire Universe with gravitational waves. eLISA is an all-sky monitor and will offer a wide view of a dynamic cosmos using gravitational waves as new and unique messengers to unveil The Gravitational Universe. It provides the closest ever view of the early processes at TeV energies, has guaranteed sources in the form of verification binaries in the Milky Way, and can probe the entire Universe, from its smallest scales around singularities and black holes, all the way to cosmological dimensions., Comment: 20 pages; submitted to the European Space Agency on May 24th, 2013 for the L2/L3 selection of ESA's Cosmic Vision program

Published
2013

32. The Gravitational Universe

Author

Consortium, The eLISA, Seoane, P. Amaro, Aoudia, S., Audley, H., Auger, G., Babak, S., Baker, J., Barausse, E., Barke, S., Bassan, M., Beckmann, V., Benacquista, M., Bender, P. L., Berti, E., Binétruy, P., Bogenstahl, J., Bonvin, C., Bortoluzzi, D., Brause, N. C., Brossard, J., Buchman, S., Bykov, I., Camp, J., Caprini, C., Cavalleri, A., Cerdonio, M., Ciani, G., Colpi, M., Congedo, G., Conklin, J., Cornish, N., Danzmann, K., de Vine, G., DeBra, D., Freitag, M. Dewi, Di Fiore, L., Aguilo, M. Diaz, Diepholz, I., Dolesi, R., Dotti, M., Barranco, G. Fernández, Ferraioli, L., Ferroni, V., Finetti, N., Fitzsimons, E., Gair, J., Galeazzi, F., Garcia, A., Gerberding, O., Gesa, L., Giardini, D., Gibert, F., Grimani, C., Groot, P., Cervantes, F. Guzman, Haiman, Z., Halloin, H., Heinzel, G., Hewitson, M., Hogan, C., Holz, D., Hornstrup, A., Hoyland, D., Hoyle, C. D., Hueller, M., Hughes, S., Jetzer, P., Kalogera, V., Karnesis, N., Kilic, M., Killow, C., Klipstein, W., Kochkina, E., Korsakova, N., Krolak, A., Larson, S., Lieser, M., Littenberg, T., Livas, J., Lloro, I., Mance, D., Madau, P., Maghami, P., Mahrdt, C., Marsh, T., Mateos, I., Mayer, L., McClelland, D., McKenzie, K., McWilliams, S., Merkowitz, S., Miller, C., Mitryk, S., Moerschell, J., Mohanty, S., Monsky, A., Mueller, G., Müller, V., Nelemans, G., Nicolodi, D., Nissanke, S., Nofrarias, M., Numata, K., Ohme, F., Otto, M., Perreur-Lloyd, M., Petiteau, A., Phinney, E. S., Plagnol, E., Pollack, S., Porter, E., Prat, P., Preston, A., Prince, T., Reiche, J., Richstone, D., Robertson, D., Rossi, E. M., Rosswog, S., Rubbo, L., Ruiter, A., Sanjuan, J., Sathyaprakash, B. S., Schlamminger, S., Schutz, B., Schütze, D., Sesana, A., Shaddock, D., Shah, S., Sheard, B., Sopuerta, C. F., Spector, A., Spero, R., Stanga, R., Stebbins, R., Stede, G., Steier, F., Sumner, T., Sun, K. -X., Sutton, A., Tanaka, T., Tanner, D., Thorpe, I., Tröbs, M., Tinto, M., Tu, H. -B., Vallisneri, M., Vetrugno, D., Vitale, S., Volonteri, M., Wand, V., Wang, Y., Wanner, G., Ward, H., Ware, B., Wass, P., Weber, W. J., Yu, Y., Yunes, N., Zweifel, P., Consortium, The eLISA, Seoane, P. Amaro, Aoudia, S., Audley, H., Auger, G., Babak, S., Baker, J., Barausse, E., Barke, S., Bassan, M., Beckmann, V., Benacquista, M., Bender, P. L., Berti, E., Binétruy, P., Bogenstahl, J., Bonvin, C., Bortoluzzi, D., Brause, N. C., Brossard, J., Buchman, S., Bykov, I., Camp, J., Caprini, C., Cavalleri, A., Cerdonio, M., Ciani, G., Colpi, M., Congedo, G., Conklin, J., Cornish, N., Danzmann, K., de Vine, G., DeBra, D., Freitag, M. Dewi, Di Fiore, L., Aguilo, M. Diaz, Diepholz, I., Dolesi, R., Dotti, M., Barranco, G. Fernández, Ferraioli, L., Ferroni, V., Finetti, N., Fitzsimons, E., Gair, J., Galeazzi, F., Garcia, A., Gerberding, O., Gesa, L., Giardini, D., Gibert, F., Grimani, C., Groot, P., Cervantes, F. Guzman, Haiman, Z., Halloin, H., Heinzel, G., Hewitson, M., Hogan, C., Holz, D., Hornstrup, A., Hoyland, D., Hoyle, C. D., Hueller, M., Hughes, S., Jetzer, P., Kalogera, V., Karnesis, N., Kilic, M., Killow, C., Klipstein, W., Kochkina, E., Korsakova, N., Krolak, A., Larson, S., Lieser, M., Littenberg, T., Livas, J., Lloro, I., Mance, D., Madau, P., Maghami, P., Mahrdt, C., Marsh, T., Mateos, I., Mayer, L., McClelland, D., McKenzie, K., McWilliams, S., Merkowitz, S., Miller, C., Mitryk, S., Moerschell, J., Mohanty, S., Monsky, A., Mueller, G., Müller, V., Nelemans, G., Nicolodi, D., Nissanke, S., Nofrarias, M., Numata, K., Ohme, F., Otto, M., Perreur-Lloyd, M., Petiteau, A., Phinney, E. S., Plagnol, E., Pollack, S., Porter, E., Prat, P., Preston, A., Prince, T., Reiche, J., Richstone, D., Robertson, D., Rossi, E. M., Rosswog, S., Rubbo, L., Ruiter, A., Sanjuan, J., Sathyaprakash, B. S., Schlamminger, S., Schutz, B., Schütze, D., Sesana, A., Shaddock, D., Shah, S., Sheard, B., Sopuerta, C. F., Spector, A., Spero, R., Stanga, R., Stebbins, R., Stede, G., Steier, F., Sumner, T., Sun, K. -X., Sutton, A., Tanaka, T., Tanner, D., Thorpe, I., Tröbs, M., Tinto, M., Tu, H. -B., Vallisneri, M., Vetrugno, D., Vitale, S., Volonteri, M., Wand, V., Wang, Y., Wanner, G., Ward, H., Ware, B., Wass, P., Weber, W. J., Yu, Y., Yunes, N., and Zweifel, P.

Abstract

The last century has seen enormous progress in our understanding of the Universe. We know the life cycles of stars, the structure of galaxies, the remnants of the big bang, and have a general understanding of how the Universe evolved. We have come remarkably far using electromagnetic radiation as our tool for observing the Universe. However, gravity is the engine behind many of the processes in the Universe, and much of its action is dark. Opening a gravitational window on the Universe will let us go further than any alternative. Gravity has its own messenger: Gravitational waves, ripples in the fabric of spacetime. They travel essentially undisturbed and let us peer deep into the formation of the first seed black holes, exploring redshifts as large as z ~ 20, prior to the epoch of cosmic re-ionisation. Exquisite and unprecedented measurements of black hole masses and spins will make it possible to trace the history of black holes across all stages of galaxy evolution, and at the same time constrain any deviation from the Kerr metric of General Relativity. eLISA will be the first ever mission to study the entire Universe with gravitational waves. eLISA is an all-sky monitor and will offer a wide view of a dynamic cosmos using gravitational waves as new and unique messengers to unveil The Gravitational Universe. It provides the closest ever view of the early processes at TeV energies, has guaranteed sources in the form of verification binaries in the Milky Way, and can probe the entire Universe, from its smallest scales around singularities and black holes, all the way to cosmological dimensions., Comment: 20 pages; submitted to the European Space Agency on May 24th, 2013 for the L2/L3 selection of ESA's Cosmic Vision program

Published
2013

33. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts

Author

Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, Salem, Z, Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O'Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., De Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, Le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Bengio, Raquel Maria, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, Desouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Aljurf, Mahmoud Deeb Saeed, Bazarba-Chi, Ali, Yehuda, Dina Ben, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Matti, Bassam Francis, Nagler, Arnon, Raanani, Pia, Salem, Ziad, Abboud, C, Berman, E, Cohen, A, Cortes, J, Deangelo, D, Deininger, M, Devine, S, Druker, B, Fathi, A, Jabbour, E, Jagasia, M, Kantarjian, H, Khoury, J, Laneuville, P, Larson, R, Lipton, J, Moore, J, Mughal, T, O'Brien, S, Pinilla-Ibarz, J, Quintas-Cardama, A, Radich, J, Reddy, V, Schiffer, C, Shah, N, Shami, P, Silver, R, Snyder, D, Stone, R, Talpaz, M, Tefferi, A, Van Etten, R, Wetzler, M, Abruzzese, E, Apperley, J, Breccia, M, Byrne, J, Cervantes, F, Chelysheva, E, Clark, R, De Lavallade, H, Dyagil, I, Gambacorti-Passerini, C, Goldman, J, Haznedaroglu, I, Hjorth-Hansen, H, Holyoake, T, Huntly, B, Le Coutre, P, Lomaia, E, Mahon, F, Marin-Costa, D, Martinelli, G, Mayer, J, Milojkovic, D, Olavarria, E, Porkka, K, Richter, J, Rousselot, P, Saglio, G, Saydam, G, Stentoft, J, Turkina, A, Vigneri, P, Zaritskey, A, Aguayo, A, Ayala, M, Bendit, I, Bengio, R, Best, C, Bullorsky, E, Cervera, E, Desouza, C, Fanilla, E, Gomez-Almaguer, D, Hamerschlak, N, Lopez, J, Magarinos, A, Meillon, L, Milone, J, Moiraghi, B, Pasquini, R, Pavlovsky, C, Ruiz-Arguelles, G, Spector, N, Arthur, C, Browett, P, Grigg, A, Jianda, H, Huang, X, Hughes, T, Jiang, Q, Jootar, S, Kim, D, Malhotra, H, Malhotra, P, Matsumura, I, Melo, J, Ohnishi, K, Ohno, R, Saikia, T, Schwarer, A, Takahashi, N, Tam, C, Tauchi, T, Usuki, K, Wang, J, Abdel-Rahman, F, Aljurf, M, Bazarba-Chi, A, Yehuda, D, Chaudhri, N, Durosinmi, M, Kamel, H, Louw, V, Matti, B, Nagler, A, Raanani, P, Salem, Z, Abboud, Camille, Berman, Ellin, Cohen, Adam, Cortes, Jorge, DeAngelo, Daniel, Deininger, Michael, Devine, Steven, Druker, Brian, Fathi, Amir, Jabbour, Elias, Jagasia, Madan, Kantarjian, Hagop, Khoury, Jean, Laneuville, Pierre, Larson, Richard, Lipton, Jeffrey, Moore, Joseph O., Mughal, Tariq, O'Brien, Susan, Pinilla-Ibarz, Javier, Quintas-Cardama, Alfonso, Radich, Jerald, Reddy, Vishnu, Schiffer, Charles, Shah, Neil, Shami, Paul, Silver, Richard T., Snyder, David, Stone, Richard, Talpaz, Moshe, Tefferi, Ayalew, Van Etten, Richard A., Wetzler, Meir, Abruzzese, Elisabetta, Apperley, Jane, Breccia, Massimo, Byrne, Jenny, Cervantes, Francisco, Chelysheva, Ekaterina, Clark, R. E., De Lavallade, Hugues, Dyagil, Iryna, Gambacorti-Passerini, Carlo, Goldman, John, Haznedaroglu, Ibrahim, Hjorth-Hansen, Henrik, Holyoake, Tessa, Huntly, Brian, Le Coutre, Philipp, Lomaia, Elza, Mahon, Francois-Xavier, Marin-Costa, David, Martinelli, Giovanni, Mayer, Jiri, Milojkovic, Dragana, Olavarria, Eduardo, Porkka, Kimmo, Richter, Johan, Rousselot, Philippe, Saglio, Giuseppe, Saydam, Guray, Stentoft, Jesper, Turkina, Anna, Vigneri, Paolo, Zaritskey, Andrey, Aguayo, Alvaro, Ayala, Manuel, Bendit, Israel, Bengio, Raquel Maria, Best, Carlos, Bullorsky, Eduardo, Cervera, Eduardo, Desouza, Carmino, Fanilla, Ernesto, Gomez-Almaguer, David, Hamerschlak, Nelson, Lopez, Jose, Magarinos, Alicia, Meillon, Luis, Milone, Jorge, Moiraghi, Beatriz, Pasquini, Ricardo, Pavlovsky, Carolina, Ruiz-Arguelles, Guillermo J., Spector, Nelson, Arthur, Christopher, Browett, Peter, Grigg, Andrew, Hu, Jianda, Huang, Xiao-jun, Hughes, Tim, Jiang, Qian, Jootar, Saengsuree, Kim, Dong-Wook, Malhotra, Hemant, Malhotra, Pankaj, Matsumura, Itaru, Melo, Junia, Ohnishi, Kazunori, Ohno, Ryuzo, Saikia, Tapan, Schwarer, Anthony P., Takahashi, Naoto, Tam, Constantine, Tauchi, Tetsuzo, Usuki, Kensuke, Wang, Jianxiang, Abdel-Rahman, Fawzi, Aljurf, Mahmoud Deeb Saeed, Bazarba-Chi, Ali, Yehuda, Dina Ben, Chaudhri, Naeem, Durosinmi, Muheez, Kamel, Hossam, Louw, Vernon, Matti, Bassam Francis, Nagler, Arnon, Raanani, Pia, and Salem, Ziad

Abstract

As a group of more than 100 experts in chronic myeloid leukemia (CML), we draw attention to the high prices of cancer drugs, with the particular focus on the prices of approved tyrosine kinase inhibitors for the treatment of CML. This editorial addresses the multiple factors involved in cancer drug pricing and their impact on individual patients and health care policies, and argues for the need to (1) lower the prices of cancer drugs to allow more patients to afford them and (2) maintain sound long-term health care policies.

Published
2013

34. Confianza, normas y participación: Análisis de organi- zaciones de productores lecheros en méxico

Author

Camacho, J.H., Aguilar, I., Cervantes, F., Camacho, J.H., Aguilar, I., and Cervantes, F.

Abstract

his study examines the relationship between trust, norms and participation in social networks in two dairy organizations located in the Teca- machalco basin of the State of Puebla, Mexico. For the analysis we utilize principal compo- nents, correlation and multiple linear regression. Principal component analysis revealed three underlying factors. We performed a reliability analysis for each component to determine the degree of consistency of the additive scale constructed. Then, we built a linear multiple regression model with trustiness as the dependent variable; shared norms and participation in groups were used as explanatory variables (also controlling by producers' age and sex, herd's size and organization affiliation). Analysis of variance concludes that the model is statistically significant (p<0.05). A positive and statistically significant relationship of shared norms and participation with trustiness is confirmed. Nevertheless, the results suggest that although expected theoretical relationships work well, there is some specificities for each group., Este estudio analiza la relación entre confian- za, normas y participación en redes sociales en dos organizaciones de productores lecheros de la cuenca de Tecamachalco, en el estado mexica- no de Puebla. Se utiliza un análisis de componen- tes principales, índices de correlación y regresión lineal múltiple. El método de componentes reveló tres factores subyacentes a los que se les realizó un análisis de fiabilidad para conocer el grado de consistencia de la escala aditiva construida. Se estableció un modelo lineal de regresión múltiple, en dónde la Confianza en el grupo se tomó como variable dependiente, mientras que Normas com- partidas y Participación en grupos son variables explicativas (en conjunto con variables de control como edad de los productores, sexo, tamaño del hato lechero y organización a la que pertenecen). El análisis de varianza reveló que el modelo es estadísticamente significativo (p<0,05). Se con- firma el efecto positivo que tienen tanto la partici- pación en redes como las normas sobre la con- fianza. Sin embargo, los hallazgos obtenidos para las dos organizaciones estudiadas permiten afir- mar que, si bien esta relación es cierta, no se presentó de la misma manera en los dos grupos.

Published
2012

35. Confianza, normas y participación: Análisis de organi- zaciones de productores lecheros en méxico

Author

Camacho, J.H., Aguilar, I., Cervantes, F., Camacho, J.H., Aguilar, I., and Cervantes, F.

Abstract

his study examines the relationship between trust, norms and participation in social networks in two dairy organizations located in the Teca- machalco basin of the State of Puebla, Mexico. For the analysis we utilize principal compo- nents, correlation and multiple linear regression. Principal component analysis revealed three underlying factors. We performed a reliability analysis for each component to determine the degree of consistency of the additive scale constructed. Then, we built a linear multiple regression model with trustiness as the dependent variable; shared norms and participation in groups were used as explanatory variables (also controlling by producers' age and sex, herd's size and organization affiliation). Analysis of variance concludes that the model is statistically significant (p<0.05). A positive and statistically significant relationship of shared norms and participation with trustiness is confirmed. Nevertheless, the results suggest that although expected theoretical relationships work well, there is some specificities for each group., Este estudio analiza la relación entre confian- za, normas y participación en redes sociales en dos organizaciones de productores lecheros de la cuenca de Tecamachalco, en el estado mexica- no de Puebla. Se utiliza un análisis de componen- tes principales, índices de correlación y regresión lineal múltiple. El método de componentes reveló tres factores subyacentes a los que se les realizó un análisis de fiabilidad para conocer el grado de consistencia de la escala aditiva construida. Se estableció un modelo lineal de regresión múltiple, en dónde la Confianza en el grupo se tomó como variable dependiente, mientras que Normas com- partidas y Participación en grupos son variables explicativas (en conjunto con variables de control como edad de los productores, sexo, tamaño del hato lechero y organización a la que pertenecen). El análisis de varianza reveló que el modelo es estadísticamente significativo (p<0,05). Se con- firma el efecto positivo que tienen tanto la partici- pación en redes como las normas sobre la con- fianza. Sin embargo, los hallazgos obtenidos para las dos organizaciones estudiadas permiten afir- mar que, si bien esta relación es cierta, no se presentó de la misma manera en los dos grupos.

Published
2012

36. Philadelphia-negative classical myeloproliferative neoplasms:critical concepts and management recommendations from European leukemiaNet

Author

Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.-J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., Tefferi, A., Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.-J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., and Tefferi, A.

Abstract

We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

Published
2011

37. Philadelphia-negative classical myeloproliferative neoplasms:critical concepts and management recommendations from European leukemiaNet

Author

Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.-J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., Tefferi, A., Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.-J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., and Tefferi, A.

Abstract

We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

Published
2011

38. Philadelphia-negative classical myeloproliferative neoplasms:critical concepts and management recommendations from European leukemiaNet

Author

Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.-J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., Tefferi, A., Barbui, T., Barosi, G., Birgegard, G., Cervantes, F., Finazzi, G., Griesshammer, M., Harrison, C., Hasselbalch, H.C., Hehlmann, R., Hoffman, R., Kiladjian, J.-J., Kröger, N., Mesa, R., McMullin, M.F., Pardanani, A., Passamonti, F., Vannucchi, A.M., Reiter, A., Silver, R.T., Verstovsek, S., and Tefferi, A.

Abstract

We present a review of critical concepts and produce recommendations on the management of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring, response definition, first- and second-line therapy, and therapy for special issues. Key questions were selected according the criterion of clinical relevance. Statements were produced using a Delphi process, and two consensus conferences involving a panel of 21 experts appointed by the European LeukemiaNet (ELN) were convened. Patients with polycythemia vera (PV) and essential thrombocythemia (ET) should be defined as high risk if age is greater than 60 years or there is a history of previous thrombosis. Risk stratification in primary myelofibrosis (PMF) should start with the International Prognostic Scoring System (IPSS) for newly diagnosed patients and dynamic IPSS for patients being seen during their disease course, with the addition of cytogenetics evaluation and transfusion status. High-risk patients with PV should be managed with phlebotomy, low-dose aspirin, and cytoreduction, with either hydroxyurea or interferon at any age. High-risk patients with ET should be managed with cytoreduction, using hydroxyurea at any age. Monitoring response in PV and ET should use the ELN clinicohematologic criteria. Corticosteroids, androgens, erythropoiesis-stimulating agents, and immunomodulators are recommended to treat anemia of PMF, whereas hydroxyurea is the first-line treatment of PMF-associated splenomegaly. Indications for splenectomy include symptomatic portal hypertension, drug-refractory painful splenomegaly, and frequent RBC transfusions. The risk of allogeneic stem-cell transplantation-related complications is justified in transplantation-eligible patients whose median survival time is expected to be less than 5 years.

Published
2011

39. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: A report on 241 cases

Author

Kiladjian, J.J., Cervantes, F. (Francisco), Leebeek, F.W.G. (Frank), Marzac, C. (Christophe), Cassinat, B. (Bruno), Chevret, S. (Sylvie), Cazals-Hatem, D. (Dominique), Plessier, A. (Aurelie), Garcia-Pagan, J.C. (Juan Carlos), Darwish Murad, S. (Sarwa), Raffa, S. (Sebastian), Janssen, H.L.A. (Harry), Gardin, C. (Claude), Cereja, S. (Sophie), Tonetti, C. (Carole), Giraudier, S. (Stéphane), Condat, B. (Bertrand), Casadevall, N. (Nicole), Fenaux, P. (Pierre), Valla, D.C. (Dominique Charle), Kiladjian, J.J., Cervantes, F. (Francisco), Leebeek, F.W.G. (Frank), Marzac, C. (Christophe), Cassinat, B. (Bruno), Chevret, S. (Sylvie), Cazals-Hatem, D. (Dominique), Plessier, A. (Aurelie), Garcia-Pagan, J.C. (Juan Carlos), Darwish Murad, S. (Sarwa), Raffa, S. (Sebastian), Janssen, H.L.A. (Harry), Gardin, C. (Claude), Cereja, S. (Sophie), Tonetti, C. (Carole), Giraudier, S. (Stéphane), Condat, B. (Bertrand), Casadevall, N. (Nicole), Fenaux, P. (Pierre), and Valla, D.C. (Dominique Charle)

Abstract

Myeloproliferative diseases (MPDs) represent the commonest cause of splanchnic vein thrombosis (SVT), including Budd- Chiari syndrome (BCS) and portal vein thrombosis (PVT), but their diagnosis is hampered by changes secondary to portal hypertension, while their influence in the outcome of SVT remains unclear. We assessed the diagnostic and prognostic value of JAK2 and MPL515 mutations in 241 SVT patients (104 BCS, 137 PVT). JAK2V617F was found in 45% of BCS and 34% of PVT, while JAK2 exon 12 and MPL515 mutations were not detected. JAK2V617F was found in 96.5% of patients with bone marrow (BM) changes specific for MPD and endogenous erythoid colonies, but also in 58% of those with only one feature and in 7% of those with neither feature. Stratifying MPD diagnosis first on JAK2V617F detection would have avoided BM investigations in 40% of the patients. In BCS, presence of MPD carried significantly poorer baseline prognostic features, required hepatic decompression procedures earlier, but had no impact on 5-year survival. Our results suggest that JAK2V617F testing should replace BM investigations as initial test for MPD in patients with SVT. Underlying MPD is associated with severe forms of BCS, but current therapy appears to offset deleterious effects of MPD on the medium-term outcome.

Published
2008
Full Text
View/download PDF

40. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia : results of a consensus process by an international working group

Author

Barosi, G., Besses, C., Birgegård, Gunnar, Briere, J., Cervantes, F., Finazzi, G., Gisslinger, H., Griesshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J. T., Michiels, J. J., Barbui, T., Barosi, G., Besses, C., Birgegård, Gunnar, Briere, J., Cervantes, F., Finazzi, G., Gisslinger, H., Griesshammer, M., Gugliotta, L., Harrison, C., Hasselbalch, H., Lengfelder, E., Reilly, J. T., Michiels, J. J., and Barbui, T.

Abstract

A widely accepted definition of resistance or intolerance to hydroxyurea (HU) in patients with essential thrombocythemia (ET) is lacking. An international working group (WG) was convened to develop a consensus formulation of clinically significant criteria for defining resistance/intolerance to HU in ET. To this aim, an analytic hierarchy process (AHP), a multiple-attribute decision-making technique, was used. The steps consisted of selecting the candidate criteria for defining resistance/intolerance; identifying the motivations that could influence the preference of the WG for any individual criterion; comparing the candidate criteria in a pair-wise manner; and grading them according their ability to fulfill the motivations. Every step in the model was derived by questionnaires or group discussion. The WG proposed that the definition of resistance/intolerance should require the fulfillment of at least one of the following criteria: platelet count greater than 600,000/micro l after 3 months of at least 2 g/day of HU (2.5 g/day in patients with a body weight over 80 kg); platelet count greater than 400,000/micro l and WBC less than 2500/micro l or Hb less than 10 g/dl at any dose of HU; presence of leg ulcers or other unacceptable muco-cutaneous manifestations at any dose of HU; HU-related fever.

Published
2007
Full Text
View/download PDF

41. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Author

Druker, B.J. (Brian), Guilhot, F. (François), O'Brien, S.G. (Stephen), Gathmann, I. (Insa), Kantarjian, H. (Hagop), Gattermann, N. (Norbert), Deininger, M.W.N. (Michael W.), Silver, R.A. (Angus), Goldman, J.M. (John), Stone, R. (Richard), Cervantes, F. (Francisco), Hochhaus, A. (Andreas), Powell, B.L. (Bayard), Gabrilove, J.L. (Janice), Rousselot, P. (Philippe), Reiffers, J. (Josy), Cornelissen, J.J. (Jan), Hughes, T. (Timothy), Agis, H. (Hermine), Fischer, T. (Thomas), Verhoef, G.E.G. (Gregor), Shepherd, J. (John), Saglio, G., Gratwohl, A. (Alois), Nielsen, J.L. (Johan), Radich, J.P. (Jerald), Simonsson, B. (Bengt), Taylor, K. (Kent), Baccarani, M. (Michele), So, C. (Charlene), Letvak, L. (Laurie), Larson, R.A. (Richard), Druker, B.J. (Brian), Guilhot, F. (François), O'Brien, S.G. (Stephen), Gathmann, I. (Insa), Kantarjian, H. (Hagop), Gattermann, N. (Norbert), Deininger, M.W.N. (Michael W.), Silver, R.A. (Angus), Goldman, J.M. (John), Stone, R. (Richard), Cervantes, F. (Francisco), Hochhaus, A. (Andreas), Powell, B.L. (Bayard), Gabrilove, J.L. (Janice), Rousselot, P. (Philippe), Reiffers, J. (Josy), Cornelissen, J.J. (Jan), Hughes, T. (Timothy), Agis, H. (Hermine), Fischer, T. (Thomas), Verhoef, G.E.G. (Gregor), Shepherd, J. (John), Saglio, G., Gratwohl, A. (Alois), Nielsen, J.L. (Johan), Radich, J.P. (Jerald), Simonsson, B. (Bengt), Taylor, K. (Kent), Baccarani, M. (Michele), So, C. (Charlene), Letvak, L. (Laurie), and Larson, R.A. (Richard)

Abstract

BACKGROUND: The cause of chronic myeloid leukemia (CML) is a constitutively active BCR-ABL tyrosine kinase. Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy. METHODS: We randomly assigned 553 patients to receive imatinib and 553 to receive interferon alfa plus cytarabine and then evaluated them for overall and event-free survival; progression to accelerated-phase CML or blast crisis; hematologic, cytogenetic, and molecular responses; and adverse events. RESULTS: The median follow-up was 60 months. Kaplan-Meier estimates of cumulative best rates of complete cytogenetic response among patients receiving imatinib were 69% by 12 months and 87% by 60 months. An estimated 7% of patients progressed to accelerated-phase CML or blast crisis, and the estimated overall survival of patients who received imatinib as initial therapy was 89% at 60 months. Patients who had a complete cytogenetic response or in whom levels of BCR-ABL transcripts had fallen by at least 3 log had a significantly lower risk of disease progression than did patients without a complete cytogenetic response (P<0.001). Grade 3 or 4 adverse events diminished over time, and there was no clinically significant change in the profile of adverse events. CONCLUSIONS: After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients. Copyright

Published
2006
Full Text
View/download PDF

42. Imatinib compared with interferon and low-dose cytarabine for newlydiagnosed chronic-phase chronic myeloid leukemia.

Author

O'Brien, SG, Guilhot, F, Larson, RA, Gathmann, I, Baccarani, M, Cervantes, F, Cornelissen, JJ, Fischer, T, Hochhaus, A, Hughes, T, Lechner, K, Nielsen, JL, Rousselot, P, Reiffers, J, Saglio, G, Shepherd, J, Simonsson, B, Gratwohl, A, Goldman, JM, Kantarjian, H, Taylor, K, Verhoef, G, Bolton, AE, Capdeville, R, Druker, BJ, O'Brien, SG, Guilhot, F, Larson, RA, Gathmann, I, Baccarani, M, Cervantes, F, Cornelissen, JJ, Fischer, T, Hochhaus, A, Hughes, T, Lechner, K, Nielsen, JL, Rousselot, P, Reiffers, J, Saglio, G, Shepherd, J, Simonsson, B, Gratwohl, A, Goldman, JM, Kantarjian, H, Taylor, K, Verhoef, G, Bolton, AE, Capdeville, R, and Druker, BJ

Published
2003

43. Imatinib compared with interferon and low-dose cytarabine for newlydiagnosed chronic-phase chronic myeloid leukemia.

Author

O'Brien, SG, Guilhot, F, Larson, RA, Gathmann, I, Baccarani, M, Cervantes, F, Cornelissen, JJ, Fischer, T, Hochhaus, A, Hughes, T, Lechner, K, Nielsen, JL, Rousselot, P, Reiffers, J, Saglio, G, Shepherd, J, Simonsson, B, Gratwohl, A, Goldman, JM, Kantarjian, H, Taylor, K, Verhoef, G, Bolton, AE, Capdeville, R, Druker, BJ, O'Brien, SG, Guilhot, F, Larson, RA, Gathmann, I, Baccarani, M, Cervantes, F, Cornelissen, JJ, Fischer, T, Hochhaus, A, Hughes, T, Lechner, K, Nielsen, JL, Rousselot, P, Reiffers, J, Saglio, G, Shepherd, J, Simonsson, B, Gratwohl, A, Goldman, JM, Kantarjian, H, Taylor, K, Verhoef, G, Bolton, AE, Capdeville, R, and Druker, BJ

Published
2003

44. Clinical Observations, Interventions, and Therapeutic Trials. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia

Author

Guardiola, P., Anderson, J., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., Witte, T.J.M. de, Deeg, H.J., Gluckman, E., Guardiola, P., Anderson, J., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., Witte, T.J.M. de, Deeg, H.J., and Gluckman, E.

Abstract

Item does not contain fulltext

Published
1999

45. Clinical Observations, Interventions, and Therapeutic Trials. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia

Author

Guardiola, P., Anderson, J., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., Witte, T.J.M. de, Deeg, H.J., Gluckman, E., Guardiola, P., Anderson, J., Bandini, G., Cervantes, F., Runde, V., Arcese, W., Bacigalupo, A., Przepiorka, D., O'Donnell, M.R., Polchi, P., Buzyn, A., Sutton, L., Cazals-Hatem, D., Sale, G., Witte, T.J.M. de, Deeg, H.J., and Gluckman, E.

Abstract

Item does not contain fulltext

Published
1999

Catalog

Books, media, physical & digital resources
See catalog results